Gargas ML - Search Results

1

Improving cancer dose-response characterization by using physiologically based pharmacokinetic modeling: an analysis of pooled data for acrylonitrile-induced brain tumors to assess cancer potency in the rat.

Kirman CR, Hays SM, Kedderis GL, Gargas ML, Strother DE. Kirman CR, et al. Among authors: gargas ml. Risk Anal. 2000 Feb;20(1):135-51. doi: 10.1111/0272-4332.00013. Risk Anal. 2000. PMID: 10795346

2

Addressing nonlinearity in the exposure-response relationship for a genotoxic carcinogen: cancer potency estimates for ethylene oxide.

Kirman CR, Sweeney LM, Teta MJ, Sielken RL, Valdez-Flores C, Albertini RJ, Gargas ML. Kirman CR, et al. Among authors: gargas ml. Risk Anal. 2004 Oct;24(5):1165-83. doi: 10.1111/j.0272-4332.2004.00517.x. Risk Anal. 2004. PMID: 15563286

3

Using physiologically-based pharmacokinetic modeling to address nonlinear kinetics and changes in rodent physiology and metabolism due to aging and adaptation in deriving reference values for propylene glycol methyl ether and propylene glycol methyl ether acetate.

Kirman CR, Sweeney LM, Corley R, Gargas ML. Kirman CR, et al. Among authors: gargas ml. Risk Anal. 2005 Apr;25(2):271-84. doi: 10.1111/j.1539-6924.2005.00588.x. Risk Anal. 2005. PMID: 15876203

4

Cancer dose--response assessment for acrylonitrile based upon rodent brain tumor incidence: use of epidemiologic, mechanistic, and pharmacokinetic support for nonlinearity.

Kirman CR, Gargas ML, Marsh GM, Strother DE, Klaunig JE, Collins JJ, Deskin R. Kirman CR, et al. Among authors: gargas ml. Regul Toxicol Pharmacol. 2005 Oct;43(1):85-103. doi: 10.1016/j.yrtph.2005.06.007. Regul Toxicol Pharmacol. 2005. PMID: 16099568

5

Derivation of noncancer reference values for acrylonitrile.

Kirman CR, Sweeney LM, Gargas ML, Strother DE, Collins JJ, Deskin R. Kirman CR, et al. Among authors: gargas ml. Risk Anal. 2008 Oct;28(5):1375-94. doi: 10.1111/j.1539-6924.2008.01101.x. Epub 2008 Aug 21. Risk Anal. 2008. PMID: 18761732

6

Physiologically based pharmacokinetic model parameter estimation and sensitivity and variability analyses for acrylonitrile disposition in humans.

Sweeney LM, Gargas ML, Strother DE, Kedderis GL. Sweeney LM, et al. Among authors: gargas ml. Toxicol Sci. 2003 Jan;71(1):27-40. doi: 10.1093/toxsci/71.1.27. Toxicol Sci. 2003. PMID: 12520073

7

Quantitative risk analysis for N-methyl pyrrolidone using physiologically based pharmacokinetic and benchmark dose modeling.

Poet TS, Kirman CR, Bader M, van Thriel C, Gargas ML, Hinderliter PM. Poet TS, et al. Among authors: gargas ml. Toxicol Sci. 2010 Feb;113(2):468-82. doi: 10.1093/toxsci/kfp264. Epub 2009 Oct 29. Toxicol Sci. 2010. PMID: 19875680

8

A physiologically based dosimetry description of acrylonitrile and cyanoethylene oxide in the rat.

Gargas ML, Andersen ME, Teo SK, Batra R, Fennell TR, Kedderis GL. Gargas ML, et al. Toxicol Appl Pharmacol. 1995 Oct;134(2):185-94. doi: 10.1006/taap.1995.1183. Toxicol Appl Pharmacol. 1995. PMID: 7570594

9

Determination of tissue partition coefficients for volatile tissue-reactive chemicals: acrylonitrile and its metabolite 2-cyanoethylene oxide.

Teo SK, Kedderis GL, Gargas ML. Teo SK, et al. Among authors: gargas ml. Toxicol Appl Pharmacol. 1994 Sep;128(1):92-6. doi: 10.1006/taap.1994.1184. Toxicol Appl Pharmacol. 1994. PMID: 8079360

10

Refinement and verification of the physiologically based dosimetry description for acrylonitrile in rats.

Kedderis GL, Teo SK, Batra R, Held SD, Gargas ML. Kedderis GL, et al. Among authors: gargas ml. Toxicol Appl Pharmacol. 1996 Oct;140(2):422-35. doi: 10.1006/taap.1996.0239. Toxicol Appl Pharmacol. 1996. PMID: 8887460

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

104 results

Search Page

Filters